DK0692970T3 - Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli - Google Patents
Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sliInfo
- Publication number
- DK0692970T3 DK0692970T3 DK94914023T DK94914023T DK0692970T3 DK 0692970 T3 DK0692970 T3 DK 0692970T3 DK 94914023 T DK94914023 T DK 94914023T DK 94914023 T DK94914023 T DK 94914023T DK 0692970 T3 DK0692970 T3 DK 0692970T3
- Authority
- DK
- Denmark
- Prior art keywords
- actin
- contents
- pathological
- viscosity
- sludge
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/042,247 US5464817A (en) | 1990-04-11 | 1993-04-02 | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
| PCT/US1994/003667 WO1994022465A1 (en) | 1993-04-02 | 1994-04-04 | Method for reducing the viscosity of pathological mucoid airway contents in the respiratoy tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0692970T3 true DK0692970T3 (da) | 1999-12-06 |
Family
ID=21920852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94914023T DK0692970T3 (da) | 1993-04-02 | 1994-04-04 | Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US5464817A (ko) |
| EP (1) | EP0692970B1 (ko) |
| JP (2) | JPH08510998A (ko) |
| KR (1) | KR100308679B1 (ko) |
| CN (1) | CN1107521C (ko) |
| AT (1) | ATE182790T1 (ko) |
| AU (1) | AU695033B2 (ko) |
| BR (1) | BR9405856A (ko) |
| CA (1) | CA2159205A1 (ko) |
| DE (1) | DE69419907T2 (ko) |
| DK (1) | DK0692970T3 (ko) |
| ES (1) | ES2135576T3 (ko) |
| GB (1) | GB2293102B (ko) |
| GR (1) | GR3031753T3 (ko) |
| NO (1) | NO953862D0 (ko) |
| SG (1) | SG49574A1 (ko) |
| WO (1) | WO1994022465A1 (ko) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464817A (en) * | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
| US5691160A (en) * | 1992-08-14 | 1997-11-25 | Biogen, Inc. | Effects of actin filaments of fibrin clot structure and lysis |
| US5593964A (en) * | 1993-10-07 | 1997-01-14 | The George Washington University Medical Center | Method of treating septic shock by preventing actin polymerization |
| US5578570A (en) * | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
| US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
| BR9510323A (pt) * | 1995-02-24 | 1997-11-11 | Genentech Inc | Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica |
| SK284191B6 (sk) | 1995-02-24 | 2004-10-05 | Genentech, Inc. | Aktín-rezistentný variant humánnej DNázy I |
| PT854927E (pt) * | 1995-10-10 | 2008-09-08 | Genentech Inc | Variantes da adnase i humana |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| DE69716460T2 (de) | 1996-12-04 | 2003-06-26 | Renovo Ltd | Wundheilung und behandlung von fibrose |
| EP1249244A1 (en) * | 2001-04-13 | 2002-10-16 | Universiteit Gent | Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease |
| BR0207725A (pt) * | 2001-12-28 | 2004-03-23 | Daiichi Suntory Biomedical Res | Promotores do crescimento e/ou da diferenciação de células-tronco hematopoiéticas e/ou progenitores hematopoiéticos |
| WO2005004904A1 (fr) * | 2003-07-14 | 2005-01-20 | Dmitry Dmitrievich Genkin | Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes) |
| US8431123B2 (en) * | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| US8710012B2 (en) * | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
| US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| PL1694342T3 (pl) * | 2003-11-12 | 2021-07-05 | Trustees Of The University Of Pennsylvania | Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej |
| US9408891B2 (en) * | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
| US8518457B2 (en) * | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
| CN1980694B (zh) * | 2004-05-12 | 2012-09-26 | 布赖汉姆妇女医院有限公司 | 凝溶胶蛋白治疗感染的用途 |
| WO2006017816A2 (en) * | 2004-08-06 | 2006-02-16 | National Jewish Medical And Research Center | Product and process for inhibition of biofilm development |
| US8916151B2 (en) * | 2005-04-25 | 2014-12-23 | Cls Therapeutics Limited | Method for treating a reduction of fertility |
| US8198094B2 (en) | 2006-03-15 | 2012-06-12 | The Brigham And Women's Hospital, Inc. | Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis |
| ES2651619T3 (es) * | 2006-03-15 | 2018-01-29 | The Brigham And Women's Hospital, Inc. | Uso de gelsolina para tratar esclerosis múltiple y diagnosticar enfermedades neurológicas |
| ATE513557T1 (de) * | 2006-11-28 | 2011-07-15 | Cls Therapeutics Ltd | Verfahren zur behandlung von krankheiten des menschen im zusammenhang mit einem erhöhten desoxyribonucleinsäuregehalt in extrazellulären räumen von geweben und medizinische zubereitung zur durchführung des verfahrens |
| WO2008101084A2 (en) * | 2007-02-15 | 2008-08-21 | National Jewish Medical And Research Center | Methods and compositions for the disruption of biofilms |
| PL2708603T3 (pl) | 2008-01-25 | 2017-12-29 | Beth Israel Deaconess Medical Ct Inc | Diagnostyczne i terapeutyczne zastosowania gelsoliny w niewydolności nerek |
| US9603906B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Inhalable liquid formulations of DNase I |
| US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| CN108289932A (zh) | 2015-05-22 | 2018-07-17 | D·D·格恩金 | 胞外dna作为神经变性的治疗靶点 |
| AU2019209770A1 (en) | 2018-01-16 | 2020-09-03 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464817A (en) * | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
| WO1991015770A1 (en) * | 1990-04-11 | 1991-10-17 | The General Hospital Corporation | Therapeutic uses of actin-binding compounds |
| US5691160A (en) * | 1992-08-14 | 1997-11-25 | Biogen, Inc. | Effects of actin filaments of fibrin clot structure and lysis |
-
1993
- 1993-04-02 US US08/042,247 patent/US5464817A/en not_active Expired - Lifetime
-
1994
- 1994-04-04 KR KR1019950704203A patent/KR100308679B1/ko not_active IP Right Cessation
- 1994-04-04 EP EP94914023A patent/EP0692970B1/en not_active Expired - Lifetime
- 1994-04-04 CA CA002159205A patent/CA2159205A1/en not_active Abandoned
- 1994-04-04 JP JP6522448A patent/JPH08510998A/ja active Pending
- 1994-04-04 ES ES94914023T patent/ES2135576T3/es not_active Expired - Lifetime
- 1994-04-04 AU AU66250/94A patent/AU695033B2/en not_active Ceased
- 1994-04-04 CN CN94191951A patent/CN1107521C/zh not_active Expired - Fee Related
- 1994-04-04 AT AT94914023T patent/ATE182790T1/de not_active IP Right Cessation
- 1994-04-04 DK DK94914023T patent/DK0692970T3/da active
- 1994-04-04 BR BR9405856A patent/BR9405856A/pt not_active Application Discontinuation
- 1994-04-04 WO PCT/US1994/003667 patent/WO1994022465A1/en active IP Right Grant
- 1994-04-04 DE DE69419907T patent/DE69419907T2/de not_active Expired - Fee Related
- 1994-04-04 GB GB9520020A patent/GB2293102B/en not_active Expired - Fee Related
- 1994-04-04 SG SG1995001962A patent/SG49574A1/en unknown
-
1995
- 1995-06-02 US US08/458,351 patent/US5656589A/en not_active Expired - Fee Related
- 1995-09-29 NO NO953862A patent/NO953862D0/no not_active Application Discontinuation
-
1999
- 1999-11-04 GR GR990402778T patent/GR3031753T3/el unknown
-
2001
- 2001-04-03 JP JP2001105286A patent/JP2001302537A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0692970B1 (en) | 1999-08-04 |
| AU6625094A (en) | 1994-10-24 |
| NO953862L (no) | 1995-09-29 |
| BR9405856A (pt) | 1996-03-05 |
| KR100308679B1 (ko) | 2001-11-30 |
| DE69419907T2 (de) | 1999-12-09 |
| CN1107521C (zh) | 2003-05-07 |
| AU695033B2 (en) | 1998-08-06 |
| NO953862D0 (no) | 1995-09-29 |
| JPH08510998A (ja) | 1996-11-19 |
| DE69419907D1 (de) | 1999-09-09 |
| GB2293102B (en) | 1996-10-09 |
| GR3031753T3 (en) | 2000-02-29 |
| CA2159205A1 (en) | 1994-10-13 |
| ATE182790T1 (de) | 1999-08-15 |
| ES2135576T3 (es) | 1999-11-01 |
| EP0692970A1 (en) | 1996-01-24 |
| SG49574A1 (en) | 1998-06-15 |
| JP2001302537A (ja) | 2001-10-31 |
| GB2293102A (en) | 1996-03-20 |
| GB9520020D0 (en) | 1995-12-06 |
| CN1122108A (zh) | 1996-05-08 |
| US5656589A (en) | 1997-08-12 |
| US5464817A (en) | 1995-11-07 |
| WO1994022465A1 (en) | 1994-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0692970T3 (da) | Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli | |
| DE69130289T2 (de) | Therapeutische verwendung von actin-bindenden verbindungen | |
| DK1094834T3 (da) | Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf | |
| NZ263344A (en) | Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use | |
| BRPI0214872B8 (pt) | unidade peptídica e multipeptídica, método ex vivo para detectar auto-anticorpos de pacientes sofrendo de artrite reumatoide e para seleção de um peptídeo adequado para o diagnóstico da referida doença, e kit de diagnóstico | |
| BR9907259A (pt) | Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso | |
| DE69635609D1 (de) | Nukleinsäure enthaltende zusammensetzung, herstellung und verwendung | |
| EA200000748A1 (ru) | Способ введения мономерных аналогов инсулина | |
| BR9809951A (pt) | Método para tratamento da obesidade | |
| ATE233096T1 (de) | Zusammensetzungen und methoden zur steigerung der darmfunktion | |
| TR199900694T2 (xx) | �nsulin C-peptitleri. | |
| DE68907679D1 (de) | Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweg-geschwuerkrankheiten. | |
| DE69331045D1 (de) | Verwendung von igf-1 | |
| ATE258797T1 (de) | Verwendung von amifostin | |
| BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
| DK0972032T3 (da) | Peptider til behandling af systemisk lupus erythematosus | |
| PT869785E (pt) | 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente | |
| BR9808392A (pt) | Uso de anticorpos de aves, e, processo para tratar infecções do trato respiratório. | |
| BR9510323A (pt) | Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica | |
| BR0011178A (pt) | Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesma | |
| BR9808866A (pt) | Moléculas retinóicas relacionadas à inibição da superprodução de endotelina-1 em doenças | |
| TR199900555T2 (xx) | Vir�slerin v�cuda yeniden yerle�mesini �nleyici madde olarak proteinerin kullan�m�. | |
| DE3586795D1 (de) | Absorptionsverbesserer fuer proteine. | |
| Kobori et al. | Immunohistological observation of the Cochlea Using the Serum from the Patient with Relapsing Polychondritis | |
| RU96123360A (ru) | Способ лечения сепсиса у новорожденных |